海爾生物(688139.SH):收購蘇州市厚宏智能科技70%股權 加速佈局智慧藥房賽道
格隆匯7月27日丨海爾生物(688139.SH)近期在接待機構投資者調研時表示,近日,公司收購了蘇州市厚宏智能科技有限公司70%股權,加速佈局智慧藥房賽道。厚宏智能科技成立於2015年,是國內智慧一體化設備及解決方案供應商,公司主要專注於醫療服務體系相關自動化設備領域研發及應用,是行業內領先的藥房全場景解決方案服務商。作為專精特新和高新技術企業,厚宏智能科技核心團隊深耕醫療自動行業技術應用十餘年,擁有發明和實用專利超百項。憑藉強勁的市場競爭力以及卓越的產品性價比,厚宏智能科技相關方案已在200多家醫院落地應用,並廣受好評。
據華經產研測算,預計到2025年,我國智慧藥房需求空間將達到132億元。此次併購是公司落地智慧服務醫療戰略的重要一環,依託厚宏智能科技豐富的產品陣容,海爾生物將快速提升在智慧藥房整體解決方案的核心競爭力,加速向“設備+平台+服務”模式升級。同時,通過資源整合、優勢互補和渠道共享,雙方將合力搭建智慧醫院服務醫療整體場景平台,快速推廣服務全國三級醫院,有望打開市縣級醫院以及海外市場。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.